<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22282" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Crescentic Glomerulonephritis (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Malvinder S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Khalid</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Malvinder Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khalid Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22282.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Crescentic glomerulonephritis&#x000a0;is characterized by the presence of&#x000a0;extensive glomerular crescents (usually greater than 50%) as the principal histologic finding. Because it often clinically presents with a rapid decline in kidney function, it is also known as rapidly progressive glomerulonephritis (RPGN). It can complicate any glomerular disease.&#x000a0;<xref ref-type="bibr" rid="article-22282.r1">[1]</xref><xref ref-type="bibr" rid="article-22282.r2">[2]</xref><xref ref-type="bibr" rid="article-22282.r3">[3]</xref><xref ref-type="bibr" rid="article-22282.r4">[4]</xref></p>
        <p>The disease can&#x000a0;be primary or secondary. Primary or idiopathic&#x000a0;crescentic glomerulonephritis is classified into the following types:</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 1&#x000a0;(anti-glomerular basement membrane [GBM] disease)&#x000a0;presents with linear deposits of immunoglobulin G (IgG)</p>
          </list-item>
          <list-item>
            <p>Type 2&#x000a0;(immune-complex mediated) presents&#x000a0;with granular deposits of immunoglobulin&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Type 3&#x000a0;(pauci-immune) presents&#x000a0;with few or no immune deposits, antineutrophil cytoplasmic antibody-associated&#x000a0;small-vessel vasculitis (SVV) that may be renal-limited or part of a systemic disease, for example, granulomatosis with polyangiitis (GPA).</p>
          </list-item>
          <list-item>
            <p>Type 4 includes combinations of types 1 and 3</p>
          </list-item>
          <list-item>
            <p>Type 5 is ANCA-negative,&#x000a0;pauci-immune renal vasculitis (5% to 10% of cases)</p>
          </list-item>
        </list>
        <p>A crescent is made up of proliferating epithelial cells that line the Bowman capsule and infiltrating macrophages. It is a marker of severe glomerular injury. The crescents may be circumferential or noncircumferential, and the presence of&#x000a0;circumferential crescents in over 80% of glomeruli portends a poor prognosis.</p>
      </sec>
      <sec id="article-22282.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>In addition to primary RPGN, secondary RPGN may occur in association with an infectious process, including poststreptococcal glomerulonephritis, infective endocarditis, occult visceral sepsis, hepatitis B infection with vasculitis and/or cryoglobulinemia or secondary to a systemic illness, systemic lupus erythematosus, Henoch-Schonlein purpura, systemic necrotizing vasculitis, essential mixed IgG and immunoglobulin M cryoglobulinemia, malignancy, relapsing polychondritis, rheumatoid vasculitis; drugs such as penicillamine, hydralazine, allopurinol (with vasculitis), rifampin; antithyroid agents such as propylthiouracil, thiamazole, carbimazole, or benzylthiouracil; aminoguanidine; or superimposed on another primary glomerular disease like membranoproliferative glomerulonephritis type 2, membranous glomerulonephritis or immunoglobulin A nephropathy.<xref ref-type="bibr" rid="article-22282.r5">[5]</xref><xref ref-type="bibr" rid="article-22282.r6">[6]</xref><xref ref-type="bibr" rid="article-22282.r7">[7]</xref></p>
      </sec>
      <sec id="article-22282.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Idiopathic crescentic glomerulonephritis accounts for fewer than 10% of all patients presenting with primary glomerulopathy. Type 3 RPGN is more common than&#x000a0;types 1 or 2. More than 50% of patients with crescentic glomerulonephritis present with acute nephritic syndrome and rapidly deteriorating renal function; however, other modes do&#x000a0;occur, such as asymptomatic 15%; nephrotic, 10%; and chronic renal failure, 15%.</p>
        <p>A seasonal predilection is observed in Type I RPGN or&#x000a0;anti-glomerular basement membrane disease with peaks&#x000a0;in spring and early summer.&#x000a0;There is male gender predilection for type 1 and type 3 RPGN. Type 1 is common in younger patients, whereas type 2 and 3 occur in older adults, with a peak incidence in the fourth to sixth decades.&#x000a0;</p>
        <p>Renal failure at presentation carries an increased risk of end-stage renal disease and death despite immunosuppressive therapy.</p>
      </sec>
      <sec id="article-22282.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>RPGN is mediated by an antibody or cellular immunity or the interaction of the two immune system&#x000a0;arms. anti-GBM disease results from the deposition of antibodies along the basement membrane&#x000a0;and/or&#x000a0;glomerular deposition of preformed soluble immune complexes. Following the disruption of the glomerular capillary, circulating cells, inflammatory mediators, and plasma proteins pass through the capillary wall into the Bowman space, which leads to the development of crescents. The major participants in crescent formation are coagulation proteins, macrophages, T cells, fibroblasts, and parietal epithelial cells. Activated macrophages contribute to the crescents by proliferating and releasing procoagulant tissue factor, interleukin-1 (IL-1), and tumor necrosis factor (TNF). T cells are not prominent components, but they play an important role in glomerular injury by antigen recognition and macrophage recruitment.</p>
      </sec>
      <sec id="article-22282.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical and laboratory presentations of all types of acute RPGN&#x000a0;are very similar. Some patients present with signs and symptoms of renal disease, such as anemia, hematuria, fluid retention, oliguria, or uremia. Weakness, nausea, and vomiting often dominate the clinical picture. Others give a history of a viral prodrome. Vague aches, frank arthritis, sinusitis, otitis, episcleritis, skin rash, neuritis, or encephalopathy are rare and are more common with multisystem disease. Oliguria, abdominal or flank pain, hemoptysis, and peripheral swelling may occur. Up to 15% of patients may be asymptomatic. Physical findings include normal or slightly elevated blood pressure, peripheral edema (10%), pallor (common), and a skin rash suggesting leukocytoclastic vasculitis.</p>
      </sec>
      <sec id="article-22282.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Complete blood count&#x000a0;may show leukocytosis and anemia; inflammatory markers such as ESR and C-reactive protein, as are&#x000a0;urea and serum creatinine, are usually elevated.&#x000a0;Urinalysis shows modest proteinuria (1 to 4 g/d), microscopic hematuria, RBCs, and RBC and WBC casts.&#x000a0;Rarely, urine findings may be minimal, and an&#x000a0;absence of active urine sediment does not exclude a diagnosis of RPGN.<xref ref-type="bibr" rid="article-22282.r8">[8]</xref><xref ref-type="bibr" rid="article-22282.r9">[9]</xref><xref ref-type="bibr" rid="article-22282.r10">[10]</xref><xref ref-type="bibr" rid="article-22282.r11">[11]</xref></p>
        <p>The immunologic evaluation may show normal&#x000a0;complement levels (C3 and C4)&#x000a0;except in type 2 RPGN, where these are decreased.&#x000a0;Circulating anti-GBM antibodies are detected in the plasma of patients with RPGN type 1, but this finding is neither 100% sensitive nor 100% specific. Anti-neutrophilic cytoplasmic autoantibodies (ANCAs), typically myeloperoxidase (MPO)&#x02013;ANCA which was&#x000a0;previously known as perinuclear ANCA (p-ANCA)&#x000a0;is observed in 80% to 90% of patients with RPGN type 3 (pauci-immune), but neither MPO-ANCA nor PR3-ANCA is 100% specific for type 3.&#x000a0;Antinuclear antibody is usually negative unless lupus-related, and&#x000a0;serum cryoglobulin levels may be elevated in cryoglobulinemias.</p>
        <list list-type="bullet">
          <list-item>
            <p>Imaging studies: Abdominal ultrasound is used to assess renal and echogenicity and to exclude obstruction.</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Renal biopsy is usually required to diagnose RPGN types 1, 2, and 3.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22282.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Principles of therapy include supportive and specific therapies.</p>
        <p>Supportive therapy involves control of infection (especially Pneumocystis jiroveci (PCP) infection with trimethoprim-sulfamethoxazole or atovaquone), control of volume status (providing dialysis if required), and smoking cessation.</p>
        <p>Specific therapy involves induction and maintenance of remission.<bold>Induction of Remission</bold></p>
        <p>The initial therapy is to induce remission, which typically consists of glucocorticoids and cyclophosphamide administration, which induces 85% to 90% of patients in 2 to 6 months, with about 75% achieving complete remission. Recently, rituximab proved a comparable substitution for&#x000a0;cyclophosphamide&#x000a0;in RAVE and RITUXIVAS trials, and it&#x000a0;may be used in patients who cannot take or refuse to take cyclophosphamide.&#x000a0;At present, the mainstay of therapy remains cyclophosphamide and steroids for induction of remission, with an option to consider rituximab in select patients. Plasma exchange&#x000a0;is useful in patients with advanced renal failure (serum creatinine greater than 500 micromol/L or requiring dialysis), in patients with severe pulmonary hemorrhage, and when associated with anti-glomerular basement membrane antibody disease. Although short-term results with plasma exchange are encouraging, the long-term benefits remain unclear, and the PEXIVAS (Plasma Exchange in Vasculitis) trial finding presented at the ERDA Meeting in the summer of 2018 (publication pending) showed no benefit of Plasma exchange in patients with ANCA vasculitis.</p>
        <p>
<bold>Maintenance of Remission</bold>
</p>
        <p>It is important to prevent relapse, as relapses are common, especially in granulomatosis with polyangiitis and microscopic polyangiitis. Continue with immunosuppressive therapy, using less toxic agents, to maintain remission and prevent relapse. Either azathioprine or methotrexate usually is used for maintenance therapy to reduce the risk of relapse. In a recent study&#x000a0;by the French Vasculitis Study Group in the MAINRISTAN trial, rituximab&#x000a0;500 mg every 6 months showed an exceptional reduction in the relapse rate with rituximab versus azathioprine&#x000a0;at 28 months (5% versus 25%)<italic toggle="yes">.</italic></p>
      </sec>
      <sec id="article-22282.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>AA (Inflammatory) amyloidosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Antiphospholipid syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Churg-Strauss syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cryoglobulinemia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse proliferative glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Idiopathic crescentic GN</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Light-chain deposition disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lupus nephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Malignant hypertension</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Microscopic polyangiitis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Poststreptococcal glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Granulomatosis with polyangiitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22282.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of crescentic glomerulonephritis is best done by an interprofessional team because of the complexity of treatment.&#x000a0;Poor prognostic factors include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Crescents in more than 80% of glomeruli, especially circumferential fibrocellular or fibrous/acellular crescents</p>
          </list-item>
          <list-item>
            <p>Initial serum creatinine level of more than 500 micromol/L or glomerular filtration rate of less than 5 mL/min at presentation</p>
          </list-item>
          <list-item>
            <p>Oliguria</p>
          </list-item>
          <list-item>
            <p>Presence of anti-GBM antibody</p>
          </list-item>
          <list-item>
            <p>Age greater than 60 years</p>
          </list-item>
        </list>
        <p>Patients receiving immunosuppressive therapy should be educated about early signs of infection and advised to see their physician or healthcare worker at any sign of infection and to monitor the WBC count.</p>
        <p>Patients on high-dose prednisone should be monitored for the development of diabetes and peptic ulcer disease and receive therapy to prevent steroid-induced osteoporosis.</p>
      </sec>
      <sec id="article-22282.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22282&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22282">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22282/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22282">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22282.s11">
        <title>References</title>
        <ref id="article-22282.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yahagi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ichikawa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shibagaki</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A Case of Self-Limiting Crescentic Immunoglobulin A Glomerulonephritis Associated with Sternoclavicular Arthritis.</article-title>
            <source>Case Rep Nephrol Dial</source>
            <year>2018</year>
            <season>Sep-Dec</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-252</page-range>
            <pub-id pub-id-type="pmid">30574506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morikawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kamiyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishimori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kasuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yashiki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Naiki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Elevated Levels of Urinary Extracellular Vesicle Fibroblast-Specific Protein 1 in Patients with Active Crescentic Glomerulonephritis.</article-title>
            <source>Nephron</source>
            <year>2019</year>
            <volume>141</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-187</page-range>
            <pub-id pub-id-type="pmid">30540988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McAdoo</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Antiglomerular Basement Membrane Disease.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>494</fpage>
            <page-range>494-503</page-range>
            <pub-id pub-id-type="pmid">30404116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salmela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rnroth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poussa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ekstrand</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prognostic Factors for Survival and Relapse in ANCA-Associated Vasculitis with Renal Involvement: A Clinical Long-Term Follow-Up Study.</article-title>
            <source>Int J Nephrol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>6369814</fpage>
            <pub-id pub-id-type="pmid">30410799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kantauskait&#x00117;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lau&#x0010d;yt&#x00117;-Cibulskien&#x00117;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miglinas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Histopathological Classification-A Prognostic Tool for Rapidly Progressive Glomerulonephritis.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2018</year>
            <month>Apr</month>
            <day>17</day>
            <volume>54</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30344248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-464</page-range>
            <pub-id pub-id-type="pmid">30404112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsui</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dokouhaki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fibrillary Glomerulonephritis with Crescentic and Necrotizing Glomerulonephritis and Concurrent Thrombotic Microangiopathy.</article-title>
            <source>Case Rep Nephrol Dial</source>
            <year>2018</year>
            <season>May-Aug</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-191</page-range>
            <pub-id pub-id-type="pmid">30320122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c7;elak&#x00131;l</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Y&#x000fc;cel</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>&#x000d6;zod</surname>
                <given-names>UK</given-names>
              </name>
              <name>
                <surname>Bek</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Anca-associated crescentic glomerulonephritis in a child with isolated renal involvement.</article-title>
            <source>J Bras Nefrol</source>
            <year>2019</year>
            <season>Apr-Jun</season>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-295</page-range>
            <pub-id pub-id-type="pmid">30199560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soliman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>F&#x000fc;l&#x000f6;p</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ploth</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>The diagnostic dilemma of new-onset crescentic glomerulonephritis following pre-eclampsia.</article-title>
            <source>Clin Nephrol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>434</fpage>
            <page-range>434-436</page-range>
            <pub-id pub-id-type="pmid">30178741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jariwala</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Laxer</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Primary Vasculitis in Childhood: GPA and MPA in Childhood.</article-title>
            <source>Front Pediatr</source>
            <year>2018</year>
            <volume>6</volume>
            <fpage>226</fpage>
            <pub-id pub-id-type="pmid">30167431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22282.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Standardized classification and reporting of glomerulonephritis.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-199</page-range>
            <pub-id pub-id-type="pmid">30124958</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
